

## Glaucoma Surgery

POLICY NUMBER	LAST REVIEW
MG.MM.SU.63fC2v2	February 14, 2025

### Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

## Definitions

<b>Aqueous Humor</b>	Clear aqueous fluid, which fills the space between the lens and retina in the anterior chamber of the eye where it flows continuously in and out of the chamber nourishing nearby tissues. The fluid exits the chamber at the open angle, where the cornea and iris meet, and flows through a spongy meshwork drain.
<b>Schlemm's Canal</b>	Circular canal in the eye that drains aqueous humor from the anterior chamber of the eye into the anterior ciliary veins.
<b>Intraocular pressure (IOP)</b>	The pressure within the eye, which is maintained by a balance between aqueous fluid secretion and fluid outflow; in glaucoma, defects that interfere with aqueous humor outflow lead to a rise in intraocular pressure resulting in degenerative compromise of optic nerve function known as progressive optic nerve atrophy and vision loss.
<b>Glaucoma</b>	<p>A group of eye diseases characterized by increased IOP), which causes pathological changes in the optic disk and defects in the field of vision.</p> <ul style="list-style-type: none"> <li>Open-angle glaucoma (OAG) — progressive form of glaucoma in which the drainage channel for the aqueous humor, composed of the attachment at the edge of the iris and the junction of the sclera and cornea, remains open, and in which serious vision-reduction occurs (advanced stages of the disease) due to tissue changes along the drainage channel.</li> <li>Primary open-angle glaucoma (POAG; aka chronic glaucoma) — most common type of glaucoma, which is associated with a build-up of aqueous fluid pressure within the</li> </ul>

	<p>eye that can lead to visual field loss and optic nerve damage (usually without any associated pain or discomfort). There is no abnormality in the anterior chamber angle; however, the aqueous fluid is unable to flow correctly.</p> <ul style="list-style-type: none"> <li>▪ Secondary open-angle glaucoma (SOAG) — open angle glaucoma resulting from other medical conditions (e.g. pseudoexfoliative glaucoma, pigmentary glaucoma) or trauma.</li> </ul> <p>The severity of glaucoma damage can be estimated using the following:</p> <ul style="list-style-type: none"> <li>▪ Mild — optic nerve abnormalities consistent with glaucoma and a normal visual field as tested with standard automated perimetry</li> <li>▪ Moderate — optic nerve abnormalities consistent with glaucoma and visual field abnormalities in one hemifield that are not within 5 degrees of fixation as tested with standard automated perimetry</li> <li>▪ Severe — optic nerve abnormalities consistent with glaucoma and visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield as tested with standard automated perimetry</li> </ul>
<b>Hypotony</b>	Abnormally low IOP of intraocular fluid; typically occurs as a complication of an underlying ocular disorder (such as uveitis or following a glaucoma surgery).
<b>Aqueous shunts (Aka aqueous drainage devices or glaucoma drainage devices, setons, tube implants and tube shunts)</b>	<p>Devices implanted into the eye to create an alternate pathway for aqueous humor drainage from the anterior or posterior eye-chamber to a space between the conjunctiva and the sclera where it is absorbed into the blood, thereby lowering IOP. These devices differ depending on explant surface areas, shape, plate thickness, the presence or absence of a valve and details of surgical installation. Generally, the risk of hypotony is reduced with aqueous shunts in comparison with trabeculectomy, but IOP outcomes are higher than after standard guarded filtration surgery.</p> <p>Other aqueous stents (e.g., microstents) are being developed as minimally penetrating methods to drain aqueous humor from the anterior chamber into Schlemm’s canal or the suprachoroidal space. These include the iStent® (Glaukos), which is a 1-mm long stent inserted into the end of Schlemm’s canal by an internal approach through the cornea and anterior chamber; and the third generation iStent supra®, which is designed for ab interno implantation into the suprachoroidal space. An advantage of ab interno shunts is that they may be inserted into the same incision and at the same time as cataract surgery. In addition, most devices do not preclude subsequent trabeculectomy if needed. It may also be possible to insert more than one shunt to achieve the desired IOP. (See <a href="#">Limitations/Exclusions</a>)</p>
<b>Trabeculectomy</b>	A surgical filtration procedure in which a portion of the trabecular meshwork is surgically removed through a superficial flap of sclera to lower the IOP by creating an alternate pathway for the aqueous fluid to flow from the anterior chamber to a bleb created in the subconjunctival space; this is currently considered the gold standard treatment for glaucoma that is refractory to medical management.

## Guideline

- A.** Laser trabeculoplasty, trabeculectomy\* or FDA-approved aqueous drainage/shunt implants\*\* are considered medically necessary for the treatment of refractory open-angle glaucoma when there is intolerance, contraindication or failure of topical/oral medication\*\*\* to control IOP. (Note: Goniotomy requests will be case-by-case reviewed)

\* Antimetabolites such as 5-Fluorouracil (5-FU) may be considered medically necessary to inhibit wound healing to prevent the conjunctiva scarring down on to the sclera.

\*\*Currently available FDA-approved implants include: Ahmed glaucoma implant, Baerveldt seton, Ex-PRESS mini glaucoma shunt, Glaucoma pressure regulator, Krupin-Denver valve implant, Molteno implant, Schocket shunt

\*\*\* First line examples include latanoprost or timolol; second line, brimonidine or dorzolamide, etc.

- B. Insertion of the Hydrus® Microstent, iStent® Trabecular Micro-Bypass Stent system, or the iStent inject® Trabecular Micro-Bypass System is considered medically necessary when used in combination with cataract surgery for mild to moderate open-angle glaucoma, and a cataract, in adult members being treated with ocular hypotensive medication.
- C. Insertion of the XEN Glaucoma Treatment System (aka XEN45) device is covered for the management of refractory glaucoma, defined as prior failure of filtering/cilioablative procedure and/or uncontrolled IOP (progressive damage and mean diurnal medicated IOP  $\geq 20$  mm Hg) on maximally tolerated medical therapy (i.e.,  $\geq 4$  classes of topical IOP-lowering medications, or fewer in the case of tolerability or efficacy issues). The insertion must be performed by an ophthalmologist with experience with trabeculectomy and bleb management.
- D. Insertion of the iStent infinite® Trabecular Micro-Bypass System Model iS3 considered medically necessary for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed
- E. Adjunctive use of anti-fibrotic agents (e.g., mitomycin C) is considered medically necessary for use Ex-PRESS® Glaucoma Filtration Device (previously the Ex-PRESS™ with the mini glaucoma shunt)

## Limitations/Exclusions

The following treatments/procedures are not considered medically necessary due to insufficient evidence of therapeutic value:

1. Transciliary filtration for glaucoma or other indications (e.g., Fugo Blade transciliary filtration, Singh filtration)
2. Ab interno trabeculectomy (trabectome) (CPT 0621T, 0622T)
3. Motorized ab interno trephination of sclera (sclerostomy), or trabecular meshwork (trabeculostomy), 1 or more, including injection of antifibrotic agents (CPT 1012T eff. 1/1/2026)
4. Beta radiation
5. Glaucoma drainage devices without FDA approval (e.g., Eyepass™ Glaucoma Implant, DeepLight® Glaucoma Treatment System, which are inserted internally)
6. Adjunctive use of anti-fibrotic agents (e.g., mitomycin C) or systemic corticosteroids with shunt implants other than the Ex-Press
7. Drug-eluting implants inserted into the lacrimal canaliculus (including punctal dilation and implant removal when performed) for glaucoma or ocular hypertension (CPT 0356T, 0444T and 0445T)
8. Requests for trabeculoplasty for ocular hypertension will be reviewed on a case-by-case basis for members who have failed pharmaceutical management

## Procedure Codes

0449T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device
0450T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; each additional device (List separately in addition to code for primary procedure)
0671T	Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more
65855	Trabeculoplasty by laser surgery
66150	Fistulization of sclera for glaucoma; trephination with iridectomy
66155	Fistulization of sclera for glaucoma; thermocauterization with iridectomy
66160	Fistulization of sclera for glaucoma; sclerectomy with punch or scissors, with iridectomy
66180	Aqueous shunt to extraocular equatorial plate reservoir, external approach; with graft
66183	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach
66184	Revision of aqueous shunt to extraocular equatorial plate reservoir; without graft
66185	Revision of aqueous shunt to extraocular equatorial plate reservoir; with graft
66710	Ciliary body destruction; cyclophotocoagulation, transscleral
66720	Ciliary body destruction; cryotherapy
66761	Iridotomy/iridectomy by laser surgery (eg, for glaucoma) (per session)
66989	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more
66991	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more
J0171	Injection, Adrenalin, epinephrine, 0.1 mg
J1120	Injection, acetazolamide sodium, up to 500 mg
J7315	Mitomycin, ophthalmic, 0.2 mg
L8612	Aqueous shunt

## ICD-10 Diagnoses

H25.10	Age-related nuclear cataract, unspecified eye
H25.11	Age-related nuclear cataract, right eye
H25.12	Age-related nuclear cataract, left eye
H25.13	Age-related nuclear cataract, bilateral

H25.20	Age-related cataract, morgagnian type, unspecified eye
H25.21	Age-related cataract, morgagnian type, right eye
H25.22	Age-related cataract, morgagnian type, left eye
H25.23	Age-related cataract, morgagnian type, bilateral
H25.811	Combined forms of age-related cataract, right eye
H25.812	Combined forms of age-related cataract, left eye
H25.813	Combined forms of age-related cataract, bilateral
H25.819	Combined forms of age-related cataract, unspecified eye
H25.89	Other age-related cataract
H25.9	Unspecified age-related cataract
H26.001	Unspecified infantile and juvenile cataract, right eye
H26.002	Unspecified infantile and juvenile cataract, left eye
H26.003	Unspecified infantile and juvenile cataract, bilateral
H26.009	Unspecified infantile and juvenile cataract, unspecified eye
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral
H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye
H26.031	Infantile and juvenile nuclear cataract, right eye
H26.032	Infantile and juvenile nuclear cataract, left eye
H26.033	Infantile and juvenile nuclear cataract, bilateral
H26.039	Infantile and juvenile nuclear cataract, unspecified eye
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye
H26.061	Combined forms of infantile and juvenile cataract, right eye
H26.062	Combined forms of infantile and juvenile cataract, left eye
H26.063	Combined forms of infantile and juvenile cataract, bilateral
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye
H26.09	Other infantile and juvenile cataract

H26.101	Unspecified traumatic cataract, right eye
H26.102	Unspecified traumatic cataract, left eye
H26.103	Unspecified traumatic cataract, bilateral
H26.109	Unspecified traumatic cataract, unspecified eye
H26.111	Localized traumatic opacities, right eye
H26.112	Localized traumatic opacities, left eye
H26.113	Localized traumatic opacities, bilateral
H26.119	Localized traumatic opacities, unspecified eye
H26.121	Partially resolved traumatic cataract, right eye
H26.122	Partially resolved traumatic cataract, left eye
H26.123	Partially resolved traumatic cataract, bilateral
H26.129	Partially resolved traumatic cataract, unspecified eye
H26.131	Total traumatic cataract, right eye
H26.132	Total traumatic cataract, left eye
H26.133	Total traumatic cataract, bilateral
H26.139	Total traumatic cataract, unspecified eye
H26.20	Unspecified complicated cataract
H26.211	Cataract with neovascularization, right eye
H26.212	Cataract with neovascularization, left eye
H26.213	Cataract with neovascularization, bilateral
H26.219	Cataract with neovascularization, unspecified eye
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye
H26.222	Cataract secondary to ocular disorders (degenerative) (inflammatory), left eye
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral
H26.229	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified eye
H26.231	Glaucomatous flecks (subcapsular), right eye
H26.232	Glaucomatous flecks (subcapsular), left eye
H26.233	Glaucomatous flecks (subcapsular), bilateral
H26.239	Glaucomatous flecks (subcapsular), unspecified eye
H26.30	Drug-induced cataract, unspecified eye
H26.31	Drug-induced cataract, right eye
H26.32	Drug-induced cataract, left eye
H26.33	Drug-induced cataract, bilateral
H26.40	Unspecified secondary cataract
H26.411	Soemmering's ring, right eye

H26.412	Soemmering's ring, left eye
H26.413	Soemmering's ring, bilateral
H26.419	Soemmering's ring, unspecified eye
H26.491	Other secondary cataract, right eye
H26.492	Other secondary cataract, left eye
H26.493	Other secondary cataract, bilateral
H26.499	Other secondary cataract, unspecified eye
H26.8	Other specified cataract
H26.9	Unspecified cataract
H40.012	Open angle with borderline findings, low risk, left eye
H40.013	Open angle with borderline findings, low risk, bilateral
H40.019	Open angle with borderline findings, low risk, unspecified eye
H40.021	Open angle with borderline findings, high risk, right eye
H40.022	Open angle with borderline findings, high risk, left eye
H40.023	Open angle with borderline findings, high risk, bilateral
H40.029	Open angle with borderline findings, high risk, unspecified eye
H40.031	Anatomical narrow angle, right eye
H40.032	Anatomical narrow angle, left eye
H40.033	Anatomical narrow angle, bilateral
H40.051	Ocular hypertension, right eye
H40.052	Ocular hypertension, left eye
H40.053	Ocular hypertension, bilateral
H40.059	Ocular hypertension, unspecified eye
H40.10X1	Unspecified open-angle glaucoma, mild stage
H40.10X2	Unspecified open-angle glaucoma, moderate stage
H40.1111	Primary open-angle glaucoma, right eye, mild stage
H40.1112	Primary open-angle glaucoma, right eye, moderate stage
H40.1113	Primary open-angle glaucoma, right eye, severe stage
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage
H40.1121	Primary open-angle glaucoma, left eye, mild stage
H40.1122	Primary open-angle glaucoma, left eye, moderate stage
H40.1123	Primary open-angle glaucoma, left eye, severe stage
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage
H40.1131	Primary open-angle glaucoma, bilateral, mild stage
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage

H40.1133	Primary open-angle glaucoma, bilateral, severe stage
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage
H40.1211	Low-tension glaucoma, right eye, mild stage
H40.1212	Low-tension glaucoma, right eye, moderate stage
H40.1213	Low-tension glaucoma, right eye, severe stage
H40.1214	Low-tension glaucoma, right eye, indeterminate stage
H40.1221	Low-tension glaucoma, left eye, mild stage
H40.1222	Low-tension glaucoma, left eye, moderate stage
H40.1223	Low-tension glaucoma, right eye, severe stage
H40.1224	Low-tension glaucoma, left eye, indeterminate stage
H40.1231	Low-tension glaucoma, bilateral, mild stage
H40.1232	Low-tension glaucoma, bilateral, moderate stage
H40.1233	Low-tension glaucoma, bilateral, severe stage
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage
H40.1311	Pigmentary glaucoma, right eye, mild stage
H40.1312	Pigmentary glaucoma, right eye, moderate stage
H40.1313	Pigmentary glaucoma, right eye, severe stage
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage
H40.1321	Pigmentary glaucoma, left eye, mild stage
H40.1322	Pigmentary glaucoma, left eye, moderate stage
H40.1323	Pigmentary glaucoma, left eye, severe stage
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage
H40.1331	Pigmentary glaucoma, left eye, mild stage
H40.1332	Pigmentary glaucoma, bilateral, moderate stage
H40.1333	Pigmentary glaucoma, bilateral, severe stage
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage



H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage
H40.89	Other specified glaucoma
Q12.0	Congenital cataract

## References

American Society of Plastic Surgeons. ASPS Recommended Insurance Coverage Criteria for Third Party Payers: Reduction Mammoplasty. March 2021. <http://www.plasticsurgery.org/for-medical-professionals/legislation-and-advocacy/health-policy-resources/recommended-insurance-coverage-criteria.html>. Accessed March 7, 2025.

Antoniuk PM. Breast augmentation and breast reduction. *Obstet Gynecol Clin North Am*. 2002;29:103-115.

Behmand RA, Tang DH, Smith DJ Jr. Outcomes in breast reduction surgery. *Ann Plast Surg*. 2000;45:575-580.

Chadbourne, EB, Zhang S, Gordon MJ, et al. Clinical outcomes in reduction mammoplasty: a systemic review and metaanalysis of published studies. *Mayo Clin Proc*. 2001;76:503-510.

Collins ED, Kerrigan CL, Kim M, et al. The effectiveness of surgical and non-surgical interventions in relieving the symptoms of macromastia. *Plast Reconstr Surg*. 2002;109:1556-1566.

Kerrigan CL, Collins ED, Kim HM, et al. Reduction mammoplasty: defining medical necessity. *Med Decis Making*. 2002;22:208-217.

Kerrigan CL, Collins ED, Striplin D, et al. The health burden of breast hypertrophy. *Plast Reconstr Surg*. 2001;108:1591-1599

Makki AS, Ghanem AA. Long term results and patient satisfaction with reduction mammoplasty. *Ann Plast Surg*. 1998;41:370-377.

Mizgala CL, MacKenzie KM. Breast reduction outcome study. *Ann Plast Surg*. 2000;44:125-134.

Raispis T, Zehring RD, Downey DL. Long-term functional results after reduction mammoplasty. *Ann Plast Surg*. 1995;34:113-116.

Schnur PL, Hoehn JG, Ilstrup DM, et al. Reduction mammoplasty: cosmetic or reconstructive procedure? *Ann Plast Surg*. 1991;27:232-237.

Schnur PL, Schnur DP, Petty PM, et al. Reduction mammoplasty: an outcome study. *Plast Reconstr Surg*. 1997;100:875-883.

Specialty-matched clinical peer review.

## Revision History

Company(ies)	DATE	REVISION
EmblemHealth	Nov. 14, 2025	Updated device branding Added CPT 0450T as covered Added CPT 1012T as investigational
EmblemHealth	Mar. 14, 2025	Transferred policy content to individual company branded template
EmblemHealth ConnectiCare	Apr. 14, 2023	Added iStent infinite® indication
EmblemHealth ConnectiCare	Sept. 11, 2020	Added a note pertaining to trabeculectomy regarding the prophylactic use of 5-Fluorouracil (5-FU)
EmblemHealth ConnectiCare	Jul. 8, 2020	Added case-by-case review language for trabeculoplasty as a treatment for ocular hypertension

EmblemHealth ConnectiCare	Jan. 10, 2020	Added iStent inject coverage and case-by-case language for goniotomy
EmblemHealth ConnectiCare	Dec. 14, 2018	Added coverage for Hydrus
EmblemHealth ConnectiCare	Sept. 14, 2018	Removed CyPass as a covered device due to Alcon recall Aug. 8, 2018
EmblemHealth ConnectiCare	Mar. 9, 2018	Added coverage for CyPass and XEN45 devices